study design–person –place –time •characterized determinants –host –agent –environment...
TRANSCRIPT
![Page 1: Study Design–Person –Place –Time •Characterized determinants –Host –Agent –Environment –Vector. Kami Memimpin We Lead Level of Evidence. Kami Memimpin We Lead Case](https://reader033.vdocuments.net/reader033/viewer/2022041900/5e5ffe54588b797411087e5e/html5/thumbnails/1.jpg)
Kami Memimpin We Lead
Kami Memimpin We Lead
Intensive Course on Basic Statistics and Research MethodologyFor MMed (Year 2), MSc and PhD Candidates
Date: July 22 – 24, 2019 Venue: DK4 & DK7
Study Design
![Page 2: Study Design–Person –Place –Time •Characterized determinants –Host –Agent –Environment –Vector. Kami Memimpin We Lead Level of Evidence. Kami Memimpin We Lead Case](https://reader033.vdocuments.net/reader033/viewer/2022041900/5e5ffe54588b797411087e5e/html5/thumbnails/2.jpg)
Kami Memimpin We Lead
Methodology
• Study design• Reference/target
population• Source population• Sampling frame• Inclusion & exclusion
criteria• Sample size
determination• Sampling techniques
• Randomization techniques
• Study time and duration
• Tools and materials• Data collection• Intended statistical test• Operational definition• Ethical consideration• Framework of study
![Page 3: Study Design–Person –Place –Time •Characterized determinants –Host –Agent –Environment –Vector. Kami Memimpin We Lead Level of Evidence. Kami Memimpin We Lead Case](https://reader033.vdocuments.net/reader033/viewer/2022041900/5e5ffe54588b797411087e5e/html5/thumbnails/3.jpg)
Kami Memimpin We Lead
Epidemiologic study design
Epidemiologic studies
Descriptive
Aggregate
Ecological studies
Individual
Case report
Case series
Incidence
Cross sectional
Analytic
Experimental
Clinical trial
Community trial
Observational
Cohort
Prospective
Retrospective
Case-control Other
![Page 4: Study Design–Person –Place –Time •Characterized determinants –Host –Agent –Environment –Vector. Kami Memimpin We Lead Level of Evidence. Kami Memimpin We Lead Case](https://reader033.vdocuments.net/reader033/viewer/2022041900/5e5ffe54588b797411087e5e/html5/thumbnails/4.jpg)
Kami Memimpin We Lead
Epidemiologic study design
Epidemiologic studies
Descriptive
Aggregate
Ecological studies
Individual
Case report
Case series
Incidence
Analytic
Experimental
Clinical trial
Community trial
Observational
Cohort
Prospective
Retrospective
Case-control OtherCross
sectional
![Page 5: Study Design–Person –Place –Time •Characterized determinants –Host –Agent –Environment –Vector. Kami Memimpin We Lead Level of Evidence. Kami Memimpin We Lead Case](https://reader033.vdocuments.net/reader033/viewer/2022041900/5e5ffe54588b797411087e5e/html5/thumbnails/5.jpg)
Kami Memimpin We Lead
• Most common study design;
– Observational study
• Cross sectional study
• Case control study
• Cohort study
– Experimental study
• Randomized clinical trial
![Page 6: Study Design–Person –Place –Time •Characterized determinants –Host –Agent –Environment –Vector. Kami Memimpin We Lead Level of Evidence. Kami Memimpin We Lead Case](https://reader033.vdocuments.net/reader033/viewer/2022041900/5e5ffe54588b797411087e5e/html5/thumbnails/6.jpg)
Kami Memimpin We Lead
Descriptive vs analytic studies
• Descriptive
– Generate hypotheses
– Answer what, who, where and when
• Analytic studies
– Test hypotheses
– Answer why and how
![Page 7: Study Design–Person –Place –Time •Characterized determinants –Host –Agent –Environment –Vector. Kami Memimpin We Lead Level of Evidence. Kami Memimpin We Lead Case](https://reader033.vdocuments.net/reader033/viewer/2022041900/5e5ffe54588b797411087e5e/html5/thumbnails/7.jpg)
Kami Memimpin We Lead
Descriptive studies
• Characterised distribution;– Person
– Place
– Time
• Characterized determinants– Host
– Agent
– Environment
– Vector
![Page 8: Study Design–Person –Place –Time •Characterized determinants –Host –Agent –Environment –Vector. Kami Memimpin We Lead Level of Evidence. Kami Memimpin We Lead Case](https://reader033.vdocuments.net/reader033/viewer/2022041900/5e5ffe54588b797411087e5e/html5/thumbnails/8.jpg)
Kami Memimpin We Lead
Level of Evidence
![Page 9: Study Design–Person –Place –Time •Characterized determinants –Host –Agent –Environment –Vector. Kami Memimpin We Lead Level of Evidence. Kami Memimpin We Lead Case](https://reader033.vdocuments.net/reader033/viewer/2022041900/5e5ffe54588b797411087e5e/html5/thumbnails/9.jpg)
Kami Memimpin We Lead
Case Report and Case Series
![Page 10: Study Design–Person –Place –Time •Characterized determinants –Host –Agent –Environment –Vector. Kami Memimpin We Lead Level of Evidence. Kami Memimpin We Lead Case](https://reader033.vdocuments.net/reader033/viewer/2022041900/5e5ffe54588b797411087e5e/html5/thumbnails/10.jpg)
Kami Memimpin We Lead
Case report and case series
• Example;– Pure Primary Extragonadal Yolk Sac Tumor involving
stomach in a Young Child: A Case Report
– Gluteal Compartment Syndrome Following Alcohol Intoxication: Case Report and Literature Review
– Atypical Cellular Blue Nevus of the Foot: A Case Report
– Severe meningococcal serogroup W sepsis presenting as myocarditis: A case report and review of literature
– Incidental neuro-endocrine tumor of the appendix: Case report and literature review
![Page 11: Study Design–Person –Place –Time •Characterized determinants –Host –Agent –Environment –Vector. Kami Memimpin We Lead Level of Evidence. Kami Memimpin We Lead Case](https://reader033.vdocuments.net/reader033/viewer/2022041900/5e5ffe54588b797411087e5e/html5/thumbnails/11.jpg)
Kami Memimpin We Lead
Case report and case series
• Case report
– Individual-level observations
– Describe particular phenomenon in a single patients
• Case series
– Describe more than one patients with similar problems
![Page 12: Study Design–Person –Place –Time •Characterized determinants –Host –Agent –Environment –Vector. Kami Memimpin We Lead Level of Evidence. Kami Memimpin We Lead Case](https://reader033.vdocuments.net/reader033/viewer/2022041900/5e5ffe54588b797411087e5e/html5/thumbnails/12.jpg)
Kami Memimpin We Lead
Case report and case series• A case report is a detailed report of the symptoms,
signs, diagnosis, treatment, and follow-up of an individual patient.
• Case reports usually describe an unusual or novel occurrence and as such, remain one of the cornerstones of medical progress and provide many new ideas in medicine.
• Some reports contain an extensive review of the relevant literature on the topic.
• The case report is a rapid short communication between busy clinicians who may not have time or resources to conduct large scale research.
![Page 13: Study Design–Person –Place –Time •Characterized determinants –Host –Agent –Environment –Vector. Kami Memimpin We Lead Level of Evidence. Kami Memimpin We Lead Case](https://reader033.vdocuments.net/reader033/viewer/2022041900/5e5ffe54588b797411087e5e/html5/thumbnails/13.jpg)
Kami Memimpin We Lead
Case report and case series
• Reason for publishing a case report1. An unexpected association between diseases or
symptoms;
2. An unexpected event in the course observing or treating a patient;
3. Findings that shed new light on the possible pathogenesis of a disease or an adverse effect;
4. Unique or rare features of a disease;
5. Unique therapeutic approaches; variation of anatomical structures.
![Page 14: Study Design–Person –Place –Time •Characterized determinants –Host –Agent –Environment –Vector. Kami Memimpin We Lead Level of Evidence. Kami Memimpin We Lead Case](https://reader033.vdocuments.net/reader033/viewer/2022041900/5e5ffe54588b797411087e5e/html5/thumbnails/14.jpg)
Kami Memimpin We Lead
Case report and case series
• Most journals publish case reports that deal with one or more of the following:– Unusual observations
– Adverse response to therapies
– Unusual combination of conditions leading to confusion
– Illustration of a new theory
– Question regarding a current theory
– Personal impact.
![Page 15: Study Design–Person –Place –Time •Characterized determinants –Host –Agent –Environment –Vector. Kami Memimpin We Lead Level of Evidence. Kami Memimpin We Lead Case](https://reader033.vdocuments.net/reader033/viewer/2022041900/5e5ffe54588b797411087e5e/html5/thumbnails/15.jpg)
Kami Memimpin We Lead
Case report and case series
• Main objective to provide a comprehensive and detailed description of the case(s) under observation.
• This allows other physicians to identify and potentially report similar cases from their practice, especially when they share geographic or specific clinical characteristics.
![Page 16: Study Design–Person –Place –Time •Characterized determinants –Host –Agent –Environment –Vector. Kami Memimpin We Lead Level of Evidence. Kami Memimpin We Lead Case](https://reader033.vdocuments.net/reader033/viewer/2022041900/5e5ffe54588b797411087e5e/html5/thumbnails/16.jpg)
Kami Memimpin We Lead
Case report and case series
• Case reports and case series are key hypothesis generating tools
• The lack of a comparison group is a major disadvantage.
• External validity (generalizability) is limited, given the biased selection of cases.
• Any association observed in a case report or acase series is prone to potentially unmeasured confounding unbeknown to the investigators.
![Page 17: Study Design–Person –Place –Time •Characterized determinants –Host –Agent –Environment –Vector. Kami Memimpin We Lead Level of Evidence. Kami Memimpin We Lead Case](https://reader033.vdocuments.net/reader033/viewer/2022041900/5e5ffe54588b797411087e5e/html5/thumbnails/17.jpg)
Kami Memimpin We Lead
Case report and case seriesAdvantages Disadvantages
One case to initiate a signal (case report)
No control
Provide stronger evidence wit multiple cases (case series)
Difficult to compare different cases
Observational Cases may not be generalizable
Educational Selection bias
Easy to do (fast and no financial support needed)
Unknown future outcome/follow-up
Identify rare manifestations of disease or drugs
![Page 18: Study Design–Person –Place –Time •Characterized determinants –Host –Agent –Environment –Vector. Kami Memimpin We Lead Level of Evidence. Kami Memimpin We Lead Case](https://reader033.vdocuments.net/reader033/viewer/2022041900/5e5ffe54588b797411087e5e/html5/thumbnails/18.jpg)
Kami Memimpin We Lead
Case report and case series
• Guidelines To Writing A Clinical Case Report
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5686928/
![Page 19: Study Design–Person –Place –Time •Characterized determinants –Host –Agent –Environment –Vector. Kami Memimpin We Lead Level of Evidence. Kami Memimpin We Lead Case](https://reader033.vdocuments.net/reader033/viewer/2022041900/5e5ffe54588b797411087e5e/html5/thumbnails/19.jpg)
Kami Memimpin We Lead
Ecological Studies
![Page 20: Study Design–Person –Place –Time •Characterized determinants –Host –Agent –Environment –Vector. Kami Memimpin We Lead Level of Evidence. Kami Memimpin We Lead Case](https://reader033.vdocuments.net/reader033/viewer/2022041900/5e5ffe54588b797411087e5e/html5/thumbnails/20.jpg)
Kami Memimpin We Lead
Ecological studies
• Example;– Abortion laws reform may reduce maternal mortality: an
ecological study in 162 countries
– Social determinants of cancer incidence and mortality around the world: an ecological study
– Seasonal variation in the internet searches for gout: an ecological study
– Happier countries, longer lives: an ecological study on the relationship between subjective sense of well-being and life expectancy
– Country Characteristics and Variation in Diabetes Prevalence among Asian Countries–an Ecological Study
![Page 21: Study Design–Person –Place –Time •Characterized determinants –Host –Agent –Environment –Vector. Kami Memimpin We Lead Level of Evidence. Kami Memimpin We Lead Case](https://reader033.vdocuments.net/reader033/viewer/2022041900/5e5ffe54588b797411087e5e/html5/thumbnails/21.jpg)
Kami Memimpin We Lead
Ecological studies
• The first approach in determining whether an association exists may be a study of group characteristics, the so-called ecologic studies.
• In ecological studies the unit of observation is the population or community.
• Disease rates and exposures are measured in each of a series of populations and their relation is examined.
• Often the information about disease and exposure is abstracted from published statistics and therefore does not require expensive or time consuming data collection.
![Page 22: Study Design–Person –Place –Time •Characterized determinants –Host –Agent –Environment –Vector. Kami Memimpin We Lead Level of Evidence. Kami Memimpin We Lead Case](https://reader033.vdocuments.net/reader033/viewer/2022041900/5e5ffe54588b797411087e5e/html5/thumbnails/22.jpg)
Kami Memimpin We Lead
Ecological studies
• The populations compared may be defined in various ways.
– Geographical comparisons
– Time trends
– Migrants
– Occupation and social class
![Page 23: Study Design–Person –Place –Time •Characterized determinants –Host –Agent –Environment –Vector. Kami Memimpin We Lead Level of Evidence. Kami Memimpin We Lead Case](https://reader033.vdocuments.net/reader033/viewer/2022041900/5e5ffe54588b797411087e5e/html5/thumbnails/23.jpg)
Kami Memimpin We Lead
Cross-sectional Studies
![Page 24: Study Design–Person –Place –Time •Characterized determinants –Host –Agent –Environment –Vector. Kami Memimpin We Lead Level of Evidence. Kami Memimpin We Lead Case](https://reader033.vdocuments.net/reader033/viewer/2022041900/5e5ffe54588b797411087e5e/html5/thumbnails/24.jpg)
Kami Memimpin We Lead
Cross-sectional Studies
• A common study design used in initially investigating the association between a specific exposure and a disease of interest
![Page 25: Study Design–Person –Place –Time •Characterized determinants –Host –Agent –Environment –Vector. Kami Memimpin We Lead Level of Evidence. Kami Memimpin We Lead Case](https://reader033.vdocuments.net/reader033/viewer/2022041900/5e5ffe54588b797411087e5e/html5/thumbnails/25.jpg)
Kami Memimpin We Lead
Cross sectional studies
Exposure +
Exposure -
Outcome +
Outcome -
![Page 26: Study Design–Person –Place –Time •Characterized determinants –Host –Agent –Environment –Vector. Kami Memimpin We Lead Level of Evidence. Kami Memimpin We Lead Case](https://reader033.vdocuments.net/reader033/viewer/2022041900/5e5ffe54588b797411087e5e/html5/thumbnails/26.jpg)
Kami Memimpin We Lead
Cross sectional studies
POPULATION
SAMPLES
IDENTIFY EXPOSURE, OUTCOME or CHARACTERISTICS simultaneously
![Page 27: Study Design–Person –Place –Time •Characterized determinants –Host –Agent –Environment –Vector. Kami Memimpin We Lead Level of Evidence. Kami Memimpin We Lead Case](https://reader033.vdocuments.net/reader033/viewer/2022041900/5e5ffe54588b797411087e5e/html5/thumbnails/27.jpg)
Kami Memimpin We Lead
Cross sectional studies
• Variables– All measured at a single point in time, – No structural distinction between predictors and outcomes
• Aim: – To learn about the characteristics of a population at one point in
time.
• Results: – Estimates of the proportion/prevalence of population
characteristics.
• Types of cross-sectional study;– Descriptive– Analytical
![Page 28: Study Design–Person –Place –Time •Characterized determinants –Host –Agent –Environment –Vector. Kami Memimpin We Lead Level of Evidence. Kami Memimpin We Lead Case](https://reader033.vdocuments.net/reader033/viewer/2022041900/5e5ffe54588b797411087e5e/html5/thumbnails/28.jpg)
Kami Memimpin We Lead
Cross sectional studies• Example;
– Prevalence of health condition, prevalence of risk behaviour & risk factor
– Characteristics of knowledge, attitude, practice
– Monitor trend over time with serial cross sectional studies
![Page 29: Study Design–Person –Place –Time •Characterized determinants –Host –Agent –Environment –Vector. Kami Memimpin We Lead Level of Evidence. Kami Memimpin We Lead Case](https://reader033.vdocuments.net/reader033/viewer/2022041900/5e5ffe54588b797411087e5e/html5/thumbnails/29.jpg)
Kami Memimpin We Lead
CROSS-SECTIONAL STUDIES
• Descriptive cross-sectional study– Purely descriptive– Used to assess the frequency and distribution of a
particular disease in a defined population– The main outcome measure is prevalence
– Example: a random sample of school children in Kelantan to estimate the prevalence of asthma among 7-12 year olds.
![Page 30: Study Design–Person –Place –Time •Characterized determinants –Host –Agent –Environment –Vector. Kami Memimpin We Lead Level of Evidence. Kami Memimpin We Lead Case](https://reader033.vdocuments.net/reader033/viewer/2022041900/5e5ffe54588b797411087e5e/html5/thumbnails/30.jpg)
Kami Memimpin We Lead
CROSS-SECTIONAL STUDIES
• Descriptive cross-sectional study
School children in Kelantan
Samples
Asthma No asthma
N=25,000
n=2,633
n=174 n=2,459
Prevalence = 6.6%
![Page 31: Study Design–Person –Place –Time •Characterized determinants –Host –Agent –Environment –Vector. Kami Memimpin We Lead Level of Evidence. Kami Memimpin We Lead Case](https://reader033.vdocuments.net/reader033/viewer/2022041900/5e5ffe54588b797411087e5e/html5/thumbnails/31.jpg)
Kami Memimpin We Lead
CROSS-SECTIONAL STUDIES
• Descriptive cross-sectional study
– Alternatively, mean or median levels of population characteristics can be estimated (e.g.: mean systolic blood pressure, mean heart rate, etc)
![Page 32: Study Design–Person –Place –Time •Characterized determinants –Host –Agent –Environment –Vector. Kami Memimpin We Lead Level of Evidence. Kami Memimpin We Lead Case](https://reader033.vdocuments.net/reader033/viewer/2022041900/5e5ffe54588b797411087e5e/html5/thumbnails/32.jpg)
Kami Memimpin We Lead
CROSS-SECTIONAL STUDIES
• Analytical cross-sectional study– Used to investigate the association between a possible
risk factor and a health outcome
– Its yields weaker evidence for causality than cohort study
– Limited ability to draw a valid conclusions about any association or possible causality because the presence of risk factors and outcomes are measured simultaneously
– Risk of recall bias since collection of information about the risk factors is also retrospective
![Page 33: Study Design–Person –Place –Time •Characterized determinants –Host –Agent –Environment –Vector. Kami Memimpin We Lead Level of Evidence. Kami Memimpin We Lead Case](https://reader033.vdocuments.net/reader033/viewer/2022041900/5e5ffe54588b797411087e5e/html5/thumbnails/33.jpg)
Kami Memimpin We Lead
CROSS-SECTIONAL STUDIES
• Analytical cross-sectional study
School children in Kelantan
Samples
Asthma No asthma
N=25,000
n=2,633
n=174 n=2,459
Prevalence = 6.6%
Parent smoking
Parent not smoking
Parent smoking
Parent not smoking
![Page 34: Study Design–Person –Place –Time •Characterized determinants –Host –Agent –Environment –Vector. Kami Memimpin We Lead Level of Evidence. Kami Memimpin We Lead Case](https://reader033.vdocuments.net/reader033/viewer/2022041900/5e5ffe54588b797411087e5e/html5/thumbnails/34.jpg)
Kami Memimpin We Lead
CROSS-SECTIONAL STUDIES
• Analytical cross-sectional study
100
450
74
2009
0
500
1000
1500
2000
2500
Asthma No Asthma
Nu
mb
er o
f p
arti
cip
ants
Exposure Based on Group
Parent smoking Parent not smoking
Chi2 (1) = 150P<0.001
![Page 35: Study Design–Person –Place –Time •Characterized determinants –Host –Agent –Environment –Vector. Kami Memimpin We Lead Level of Evidence. Kami Memimpin We Lead Case](https://reader033.vdocuments.net/reader033/viewer/2022041900/5e5ffe54588b797411087e5e/html5/thumbnails/35.jpg)
Kami Memimpin We Lead
Cross sectional studies• When to use a cross sectional study?
– When objective is to determine prevalence / proportion
– When temporality of risk (exposure outcome) is not the aim of the study
– When both, the outcome and the exposure are relatively common.
![Page 36: Study Design–Person –Place –Time •Characterized determinants –Host –Agent –Environment –Vector. Kami Memimpin We Lead Level of Evidence. Kami Memimpin We Lead Case](https://reader033.vdocuments.net/reader033/viewer/2022041900/5e5ffe54588b797411087e5e/html5/thumbnails/36.jpg)
Kami Memimpin We Lead
Cross sectional studies
• Advantages
– May study several outcomes, and several exposures
– Relatively short duration
– A good first step for a cohort study
– Yields prevalence and relative prevalence
• Disadvantages:
– Does not establish sequence of events (temporality)
– Not feasible for rare predictors or rare outcomes
– Does not yield incidence or true relative risk
![Page 37: Study Design–Person –Place –Time •Characterized determinants –Host –Agent –Environment –Vector. Kami Memimpin We Lead Level of Evidence. Kami Memimpin We Lead Case](https://reader033.vdocuments.net/reader033/viewer/2022041900/5e5ffe54588b797411087e5e/html5/thumbnails/37.jpg)
Kami Memimpin We Lead
Cohort studies
![Page 38: Study Design–Person –Place –Time •Characterized determinants –Host –Agent –Environment –Vector. Kami Memimpin We Lead Level of Evidence. Kami Memimpin We Lead Case](https://reader033.vdocuments.net/reader033/viewer/2022041900/5e5ffe54588b797411087e5e/html5/thumbnails/38.jpg)
Kami Memimpin We Lead
Cohort studies
• Cohort: a well defined group of individuals who share a common characteristics or experience.
• Example: individuals born in the same year.
• Also known as longitudinal study or follow up study.
• Participants classified according to exposure, followed up over time to ascertain outcome.
• E.g. nuclear power plant radiation exposure cancer events.
![Page 39: Study Design–Person –Place –Time •Characterized determinants –Host –Agent –Environment –Vector. Kami Memimpin We Lead Level of Evidence. Kami Memimpin We Lead Case](https://reader033.vdocuments.net/reader033/viewer/2022041900/5e5ffe54588b797411087e5e/html5/thumbnails/39.jpg)
Kami Memimpin We Lead
Cohort studies
• 2 types:
– Prospective cohort
– Retrospective cohort
![Page 40: Study Design–Person –Place –Time •Characterized determinants –Host –Agent –Environment –Vector. Kami Memimpin We Lead Level of Evidence. Kami Memimpin We Lead Case](https://reader033.vdocuments.net/reader033/viewer/2022041900/5e5ffe54588b797411087e5e/html5/thumbnails/40.jpg)
Kami Memimpin We Lead
Cohort studies
![Page 41: Study Design–Person –Place –Time •Characterized determinants –Host –Agent –Environment –Vector. Kami Memimpin We Lead Level of Evidence. Kami Memimpin We Lead Case](https://reader033.vdocuments.net/reader033/viewer/2022041900/5e5ffe54588b797411087e5e/html5/thumbnails/41.jpg)
Kami Memimpin We Lead
1. Prospective Cohort Studies
Present Future
![Page 42: Study Design–Person –Place –Time •Characterized determinants –Host –Agent –Environment –Vector. Kami Memimpin We Lead Level of Evidence. Kami Memimpin We Lead Case](https://reader033.vdocuments.net/reader033/viewer/2022041900/5e5ffe54588b797411087e5e/html5/thumbnails/42.jpg)
Kami Memimpin We Lead
![Page 43: Study Design–Person –Place –Time •Characterized determinants –Host –Agent –Environment –Vector. Kami Memimpin We Lead Level of Evidence. Kami Memimpin We Lead Case](https://reader033.vdocuments.net/reader033/viewer/2022041900/5e5ffe54588b797411087e5e/html5/thumbnails/43.jpg)
Kami Memimpin We Lead
2. Retrospective Cohort Study
Past Present
![Page 44: Study Design–Person –Place –Time •Characterized determinants –Host –Agent –Environment –Vector. Kami Memimpin We Lead Level of Evidence. Kami Memimpin We Lead Case](https://reader033.vdocuments.net/reader033/viewer/2022041900/5e5ffe54588b797411087e5e/html5/thumbnails/44.jpg)
Kami Memimpin We Lead
![Page 45: Study Design–Person –Place –Time •Characterized determinants –Host –Agent –Environment –Vector. Kami Memimpin We Lead Level of Evidence. Kami Memimpin We Lead Case](https://reader033.vdocuments.net/reader033/viewer/2022041900/5e5ffe54588b797411087e5e/html5/thumbnails/45.jpg)
Kami Memimpin We Lead
Cohort study• Advantage :
– Establish sequence of events (exposure outcome)– Can study several outcomes– Number of outcomes events grows over time– Yields incidence, relative risk and excess risk (true risk)– More control over selection of subjects– More control over measurements– Avoid bias in measuring predictors
• Disadvantage :– Requires more time, money and human resources.– Larger sample size– More expensive– Longer duration
![Page 46: Study Design–Person –Place –Time •Characterized determinants –Host –Agent –Environment –Vector. Kami Memimpin We Lead Level of Evidence. Kami Memimpin We Lead Case](https://reader033.vdocuments.net/reader033/viewer/2022041900/5e5ffe54588b797411087e5e/html5/thumbnails/46.jpg)
Kami Memimpin We Lead
Case-control studies
![Page 47: Study Design–Person –Place –Time •Characterized determinants –Host –Agent –Environment –Vector. Kami Memimpin We Lead Level of Evidence. Kami Memimpin We Lead Case](https://reader033.vdocuments.net/reader033/viewer/2022041900/5e5ffe54588b797411087e5e/html5/thumbnails/47.jpg)
Kami Memimpin We Lead
Case control studies
• When to conduct;
– To study rare disease/ outcome
– To study multiple exposures that may be related to a single outcome
– Funding or time is limited
![Page 48: Study Design–Person –Place –Time •Characterized determinants –Host –Agent –Environment –Vector. Kami Memimpin We Lead Level of Evidence. Kami Memimpin We Lead Case](https://reader033.vdocuments.net/reader033/viewer/2022041900/5e5ffe54588b797411087e5e/html5/thumbnails/48.jpg)
Kami Memimpin We Lead
Case control studies
• Subjects
– Case and control have the same population of origin
– Always start with cases, the find appropriate control
• Case:
• Have outcome of interest
• Representative sample of all cases in the general population
• Control:
• Do not have outcome of interest
• Representative sample of the general population
![Page 49: Study Design–Person –Place –Time •Characterized determinants –Host –Agent –Environment –Vector. Kami Memimpin We Lead Level of Evidence. Kami Memimpin We Lead Case](https://reader033.vdocuments.net/reader033/viewer/2022041900/5e5ffe54588b797411087e5e/html5/thumbnails/49.jpg)
Kami Memimpin We Lead
Case control studies
![Page 50: Study Design–Person –Place –Time •Characterized determinants –Host –Agent –Environment –Vector. Kami Memimpin We Lead Level of Evidence. Kami Memimpin We Lead Case](https://reader033.vdocuments.net/reader033/viewer/2022041900/5e5ffe54588b797411087e5e/html5/thumbnails/50.jpg)
Kami Memimpin We Lead
Case control studies
• Advantages
– Use for studying rare conditions (outcomes)
– Less expensive
– Relatively smaller sample size
– Shorter duration than prospective study
– Able to study multiple risk factors/exposure for 1 disease
– Yields odds ratio (estimation of true risk)
![Page 51: Study Design–Person –Place –Time •Characterized determinants –Host –Agent –Environment –Vector. Kami Memimpin We Lead Level of Evidence. Kami Memimpin We Lead Case](https://reader033.vdocuments.net/reader033/viewer/2022041900/5e5ffe54588b797411087e5e/html5/thumbnails/51.jpg)
Kami Memimpin We Lead
Case control studies
• Disadvantages
– Exposure obtained after diagnosis (disease exposure)
– Does not establish sequence of events
– Potential for bias and confounding from sampling two populations
– Dependent on the subject’s memory
– Difficult to identify appropriate control group
– Limited to one outcome variable
– Does not yield prevalence, incidence or excess risk
![Page 52: Study Design–Person –Place –Time •Characterized determinants –Host –Agent –Environment –Vector. Kami Memimpin We Lead Level of Evidence. Kami Memimpin We Lead Case](https://reader033.vdocuments.net/reader033/viewer/2022041900/5e5ffe54588b797411087e5e/html5/thumbnails/52.jpg)
Kami Memimpin We Lead
Experimental Study Design
Clinical Trials
![Page 53: Study Design–Person –Place –Time •Characterized determinants –Host –Agent –Environment –Vector. Kami Memimpin We Lead Level of Evidence. Kami Memimpin We Lead Case](https://reader033.vdocuments.net/reader033/viewer/2022041900/5e5ffe54588b797411087e5e/html5/thumbnails/53.jpg)
Kami Memimpin We Lead
Clinical Trials
• A test of a new intervention or treatment on people
• Clinical trials are a set of procedures in medical research and drug development that are conducted to allow safety and efficacy data to be collected for health interventions (e.g., drugs, diagnostics, devices, therapy protocols).
![Page 54: Study Design–Person –Place –Time •Characterized determinants –Host –Agent –Environment –Vector. Kami Memimpin We Lead Level of Evidence. Kami Memimpin We Lead Case](https://reader033.vdocuments.net/reader033/viewer/2022041900/5e5ffe54588b797411087e5e/html5/thumbnails/54.jpg)
Kami Memimpin We Lead
Clinical Trials
• A randomized controlled trial (RCT) is a specific type of scientific experiment, and the gold standard for a clinical trial.
• New treatment given to a group of patients (treated group) and another treatment given to another group of patients (control group) at the same time – concurrently controlled
• Patients allocated to groups by randomization
![Page 55: Study Design–Person –Place –Time •Characterized determinants –Host –Agent –Environment –Vector. Kami Memimpin We Lead Level of Evidence. Kami Memimpin We Lead Case](https://reader033.vdocuments.net/reader033/viewer/2022041900/5e5ffe54588b797411087e5e/html5/thumbnails/55.jpg)
Kami Memimpin We Lead
Types of Clinical Trials
• Treatment/Drug trials
• Prevention trials
• Screening trials/Diagnostic trials
• Quality-of-life studies/supportive care studies
• Genetic trials
• Etc
![Page 56: Study Design–Person –Place –Time •Characterized determinants –Host –Agent –Environment –Vector. Kami Memimpin We Lead Level of Evidence. Kami Memimpin We Lead Case](https://reader033.vdocuments.net/reader033/viewer/2022041900/5e5ffe54588b797411087e5e/html5/thumbnails/56.jpg)
Kami Memimpin We Lead
Key Features in Clinical Trials
• Intervention (experimental) studies in clinical setting Clinical trials
• Similar to cohort study, except that “exposure” are allocated rather than observed.
![Page 57: Study Design–Person –Place –Time •Characterized determinants –Host –Agent –Environment –Vector. Kami Memimpin We Lead Level of Evidence. Kami Memimpin We Lead Case](https://reader033.vdocuments.net/reader033/viewer/2022041900/5e5ffe54588b797411087e5e/html5/thumbnails/57.jpg)
Kami Memimpin We Lead
Experimental vs observational studies
Experimental studies Observational Studies
Examples Randomized Clinical TrialsQuasi-experimental trialsCluster Randomized trials
CohortCase-controlCross-sectionalCase-series
Group assignment is based on
Researcher assigns groups “Natural Conditions” (personal preference, genetics, social determinants, environment, etc)
Use “Gold Standard” for studying therapeutic interventions (treatments) or prophylactic interventions (prevention)
Association between health outcomes and exposures. This can include studies on diagnosis, prognosis, aetiology or harm
![Page 58: Study Design–Person –Place –Time •Characterized determinants –Host –Agent –Environment –Vector. Kami Memimpin We Lead Level of Evidence. Kami Memimpin We Lead Case](https://reader033.vdocuments.net/reader033/viewer/2022041900/5e5ffe54588b797411087e5e/html5/thumbnails/58.jpg)
Kami Memimpin We Lead
Advantages and Disadvantages• Advantages
– Gold standard for evaluating efficacy of therapeutic or preventive measures.
– Provides strongest evidence for causality.– Reduces influence of other determinants of exposure and
outcome (confounding) due to randomization.
• Disadvantages– Expensive, time-consuming.– Subjects may not be representative of all people who might
eventually be put on the treatment.– Ethical considerations (equipoise necessary) – believe new
treatment is at least as good as old treatment or placebo.
![Page 59: Study Design–Person –Place –Time •Characterized determinants –Host –Agent –Environment –Vector. Kami Memimpin We Lead Level of Evidence. Kami Memimpin We Lead Case](https://reader033.vdocuments.net/reader033/viewer/2022041900/5e5ffe54588b797411087e5e/html5/thumbnails/59.jpg)
Kami Memimpin We Lead
Structure of a Clinical Trial
• Recall cohort study
Exposed
Non-Exposed
Event
No Event
Event
No Event
Exposure not manipulated by researcher
![Page 60: Study Design–Person –Place –Time •Characterized determinants –Host –Agent –Environment –Vector. Kami Memimpin We Lead Level of Evidence. Kami Memimpin We Lead Case](https://reader033.vdocuments.net/reader033/viewer/2022041900/5e5ffe54588b797411087e5e/html5/thumbnails/60.jpg)
Kami Memimpin We Lead
Structure of a Clinical Trial
• Clinical trial
Exposed
Non-Exposed
Event
No Event
Event
No Event
Exposure manipulated by researcher
![Page 61: Study Design–Person –Place –Time •Characterized determinants –Host –Agent –Environment –Vector. Kami Memimpin We Lead Level of Evidence. Kami Memimpin We Lead Case](https://reader033.vdocuments.net/reader033/viewer/2022041900/5e5ffe54588b797411087e5e/html5/thumbnails/61.jpg)
Kami Memimpin We Lead
Structure of Clinical Trials
• All elements are the same as for a cohort study except that treatment is assigned by researcher (either by randomization or not) rather than by physician and patient choice.
• The “exposures” are treatments, and the “outcomes” are any possible end result of treatment
• The patients to be studied are first selected from a larger number of patients with the condition of interest.
![Page 62: Study Design–Person –Place –Time •Characterized determinants –Host –Agent –Environment –Vector. Kami Memimpin We Lead Level of Evidence. Kami Memimpin We Lead Case](https://reader033.vdocuments.net/reader033/viewer/2022041900/5e5ffe54588b797411087e5e/html5/thumbnails/62.jpg)
Kami Memimpin We Lead
Structure of Clinical Trials• Patients are then divided into two (or more) groups of
comparable prognosis. • One group, called the experimental group, is exposed to an
intervention that is believed to be better than current alternatives.
• The other group, called a control (or comparison) group, is treated the same in all ways except that its members are not exposed to the experimental intervention.
• Patients in the control group may receive a placebo, usual care, or the current best available treatment.
• The course of disease is then recorded in both groups, and differences in outcome are attributed to the intervention.
![Page 63: Study Design–Person –Place –Time •Characterized determinants –Host –Agent –Environment –Vector. Kami Memimpin We Lead Level of Evidence. Kami Memimpin We Lead Case](https://reader033.vdocuments.net/reader033/viewer/2022041900/5e5ffe54588b797411087e5e/html5/thumbnails/63.jpg)
Kami Memimpin We Lead
Structure of Clinical Trials
• The main reason for structuring clinical trials in this way is to avoid confounding when comparing the respective effects of two or more kinds of treatments.
• The validity of clinical trials depends on how well they have created equal distribution of all determinants of prognosis, other than the one being tested, in treated and control patients.
![Page 64: Study Design–Person –Place –Time •Characterized determinants –Host –Agent –Environment –Vector. Kami Memimpin We Lead Level of Evidence. Kami Memimpin We Lead Case](https://reader033.vdocuments.net/reader033/viewer/2022041900/5e5ffe54588b797411087e5e/html5/thumbnails/64.jpg)
Kami Memimpin We Lead
Elements of Clinical Trials• Ethics
– more ethical issues compared to observational studies
• Sampling – non-random / volunteer
• Intervention – allocated by researcher (in randomized trial)
• Comparison groups – may or may not have comparison group
• Allocating treatment – randomization
• Blinding – none / single / double / triple
• Assessment of outcomes – primary outcome/ secondary outcome / surrogate outcome / composite
outcome / adverse effects
![Page 65: Study Design–Person –Place –Time •Characterized determinants –Host –Agent –Environment –Vector. Kami Memimpin We Lead Level of Evidence. Kami Memimpin We Lead Case](https://reader033.vdocuments.net/reader033/viewer/2022041900/5e5ffe54588b797411087e5e/html5/thumbnails/65.jpg)
Kami Memimpin We Lead
Recap
Epidemiologic studies
Descriptive
Aggregate
Ecological studies
Individual
Case report
Case series
Incidence
Analytic
Experimental
Clinical trial
Community trial
Observational
Cohort
Prospective
Retrospective
Case-control OtherCross
sectional
![Page 66: Study Design–Person –Place –Time •Characterized determinants –Host –Agent –Environment –Vector. Kami Memimpin We Lead Level of Evidence. Kami Memimpin We Lead Case](https://reader033.vdocuments.net/reader033/viewer/2022041900/5e5ffe54588b797411087e5e/html5/thumbnails/66.jpg)
Kami Memimpin We Lead
References• Sayre, J. W., Toklu, H. Z., Ye, F., Mazza, J., & Yale, S. (2017). Case reports,
case series–from clinical practice to evidence-based medicine in graduate medical education. Cureus, 9(8).
• Guidelines To Writing A Clinical Case Report. (2017). Heart views : the official journal of the Gulf Heart Association, 18(3), 104–105. doi:10.4103/1995-705X.217857
• https://www.bmj.com/about-bmj/resources-readers/publications/epidemiology-uninitiated/6-ecological-studies
• David D Celentano, S. M., & Szklo, J. H. S. P. H. M. (2018). GordisEpidemiology: Elsevier Health Sciences.